Prognosis
Vaccine Hesitancy Rose in EU After Pause in AstraZeneca Shots
- Eurofound survey finds 34% hesitancy after March suspension
- Findings reflect a communication failure, researcher says
This article is for subscribers only.
Vaccine hesitancy increased in the European Union after the suspension of AstraZeneca Plc’s vaccine, with more than a third of adults in the bloc indicating they were unlikely to get immunized from Covid-19.
After several EU countries suspended use of Astra’s shot in mid March, 34% of respondents to an online survey by Eurofound said they were hesitant to take the vaccine. Before the pause, 25% said they were “rather unlikely” or “very unlikely” to get it.